Help
RSS
API
Feed
Maltego
Contact
Domain > chadsvasc.org
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2014-08-27
104.28.22.73
(
ClassC
)
2014-09-01
104.28.23.73
(
ClassC
)
2015-03-10
108.162.194.122
(
ClassC
)
2015-03-10
108.162.195.122
(
ClassC
)
2024-09-12
148.251.68.119
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: nginxDate: Thu, 12 Sep 2024 09:20:30 GMTContent-Type: text/htmlContent-Length: 162Connection: keep-aliveLocation: https://chadsvasc.org/ html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>nginx/center>/body>/html>
Port 443
HTTP/1.1 200 OKServer: nginxDate: Thu, 12 Sep 2024 09:20:31 GMTContent-Type: text/html;Content-Length: 32506Connection: keep-aliveAccept-Ranges: bytesX-Mod-Pagespeed: 1.14.36.1-0Vary: Accept-EncodingCache-Control: max-age0, no-cache, s-maxage10Strict-Transport-Security: max-age15768000; includeSubDomainsX-Powered-By: PleskLin !DOCTYPE html>html>head> meta charsetUTF-8> meta http-equivContent-Type contenttext/html;/> title>CHADSVASC, CHA2DS2VASC and HASBLED risk score calculator for atrial fibrillation/title> link relstylesheet typetext/css hrefcss/style3.css defer> link relshortcut icon typeimage/x-icon hreffavicon.ico> script srcjs/jquery.min.js defer>/script> script srcjs/clipboard.js defer>/script> script srcjs/helpers_array.js defer>/script> script srcjs/main.js defer>/script> script>document.addEventListener(DOMContentLoaded,function(){const clipboardnew Clipboard(.copy_paste_btm);clipboard.on(success,function(e){console.info(Action:,e.action);console.info(Text:,e.text);console.info(Trigger:,e.trigger);e.clearSelection();});clipboard.on(error,function(e){console.error(Action:,e.action);console.error(Trigger:,e.trigger);});});/script>/head>body> div idmain> div>img srcimg/logo.png altCHADSVASC and HASBLED risk score calculator/>/div> div classheader_text text_arial>Please select CHADSVASC and HASBLED risk factors, EHRA score and click copy to clipboard to copy and paste in your electronic files/div> div classtables> div classfirst_group> div classtable1> div classt_title text_arial>Chadsvasc risk factors click on present risk factors/div> table classt1 pink_table> tr> td classtable_title td1> div> div>RISK FACTORS/div> /div> /td> td classtable_title> div> div>SCORE/div> /div> /td> /tr> tr classq0 q score1 letterC> td classtd1> div> div>Congestive heart failure/div> div classhelper> div classl_arrow>/div> div classdesc>congestive_heart_failure/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq1 q score1 letterH> td classtd1> div> div>Hypertension/div> div classhelper> div classl_arrow>/div> div classdesc>Hypertension/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq2 q score2 letterA> td classtd1> div> div>Age ≥ 75/div> div classhelper> div classl_arrow>/div> div classdesc>Age ≥ 75/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>2/div> /div> /td> /tr> tr classq3 q score1 letterA2> td classtd1> div> div>Age 65-74/div> div classhelper> div classl_arrow>/div> div classdesc>Age ≥ 75/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq4 q score1 letterD> td classtd1> div> div>Diabetes mellitus/div> div classhelper> div classl_arrow>/div> div classdesc>Diabetes mellitus/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq5 q score2 letterS> td classtd1> div> div>Stroke/TIA/thrombo-embolism/div> div classhelper> div classl_arrow>/div> div classdesc>Stroke/TIA/thrombo-embolism/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>2/div> /div> /td> /tr> tr classq6 q score1 letterV> td classtd1> div> div>Vascular disease/div> div classhelper> div classl_arrow>/div> div classdesc>Vascular disease/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq7 q score1 lettersex> td classtd1> div> div>Sex Female/div> div classhelper> div classl_arrow>/div> div classdesc>Sex Female/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr> td classtable_result td1> div> div>Your score/div> /div> /td> td classtable_result result1> div> div>0/div> /div> /td> /tr> /table> div classv_arr1>img srcimg/varr.png altvarr/>/div> div classviev_results1>img srcimg/results.png altresults/>/div> div styleclear:both>/div> /div> div classtable3> div classt_title text_arial>CHADSVASC clinical risk estimation. Adapted from Lip et al. See Van den Ham et al. below for actual risks in a larger population./div> table classt1 blue_table> tr> td classtable_title td1> div> div>CHAsub>2/sub>DSsub>2/sub>VASc br>SCORE/div> /div> /td> td classtable_title td2> div> div>PATIENTS (n7329)/div> /div> /td> td classtable_title td3> div> div>ADJUSTED STROKE RATE (% year)/div> /div> /td> /tr> tr classq0 active risk_score0%> td classtd1> div> div>0/div> /div> /td> td classtd2> div> div>1/div> /div> /td> td classtd3> div> div>0%/div> /div> /td> /tr> tr classq1 risk_score1.3%> td classtd1> div> div>1/div> /div> /td> td classtd2> div> div>422/div> /div> /td> td classtd3> div> div>1.3%/div> /div> /td> /tr> tr classq2 risk_score2.2%> td classtd1> div> div>2/div> /div> /td> td classtd2> div> div>1230/div> /div> /td> td classtd3> div> div>2.2%/div> /div> /td> /tr> tr classq3 risk_score3.2%> td classtd1> div> div>3/div> /div> /td> td classtd2> div> div>1730/div> /div> /td> td classtd3> div> div>3.2%/div> /div> /td> /tr> tr classq4 risk_score4.0%> td classtd1> div> div>4/div> /div> /td> td classtd2> div> div>1718/div> /div> /td> td classtd3> div> div>4.0%/div> /div> /td> /tr> tr classq5 risk_score6.7%> td classtd1> div> div>5/div> /div> /td> td classtd2> div> div>1159/div> /div> /td> td classtd3> div> div>6.7%/div> /div> /td> /tr> tr classq6 risk_score9.8%> td classtd1> div> div>6/div> /div> /td> td classtd2> div> div>679/div> /div> /td> td classtd3> div> div>9.8%/div> /div> /td> /tr> tr classq7 risk_score9.6%> td classtd1> div> div>7/div> /div> /td> td classtd2> div> div>294/div> /div> /td> td classtd3> div> div>9.6%/div> /div> /td> /tr> tr classq8 risk_score6.7%> td classtd1> div> div>8/div> /div> /td> td classtd2> div> div>82/div> /div> /td> td classtd3> div> div>6.7%/div> /div> /td> /tr> tr classq9 risk_score15.2%> td classtd1> div> div>9/div> /div> /td> td classtd2> div> div>14/div> /div> /td> td classtd3> div> div>15.2%/div> /div> /td> /tr> /table> /div> div styleclear:both>/div> /div> div classsecond_group> div classtable2> div classt_title text_arial>HASBLED clinical characteristic click on present risk factors/div> table classt1 pink_table> tr> td classtable_title td1> div> div>CLINICAL CHARACTERISTIC/div> /div> /td> td classtable_title> div> div>POINTSbr>AWARDED/div> /div> /td> /tr> tr classq0 q score1 letterH> td classtd1> div> div>Hypertension/div> div classhelper> div classl_arrow>/div> div classdesc>Hypertension/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq1 q score1 letterA> td classtd1> div> div>Abnormal liver function/div> div classhelper> div classl_arrow>/div> div classdesc>Abnormal liver function/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq2 q score1 letterA> td classtd1> div> div>Abnormal renal function/div> div classhelper> div classl_arrow>/div> div classdesc>Abnormal renal function/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq3 q score1 letterS> td classtd1> div> div>Stroke/div> div classhelper> div classl_arrow>/div> div classdesc>Stroke/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq4 q score1 letterB> td classtd1> div> div>Bleeding/div> div classhelper> div classl_arrow>/div> div classdesc>Bleeding/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq5 q score1 letterL> td classtd1> div> div>Labile INRs/div> div classhelper> div classl_arrow>/div> div classdesc>Labile INRs/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq6 q score1 letterE> td classtd1> div> div>Elderly (Age >65)/div> div classhelper> div classl_arrow>/div> div classdesc>Elderly (e.g. >65)/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq7 q score1 letterD> td classtd1> div> div>Drugs/div> div classhelper> div classl_arrow>/div> div classdesc>Drugs/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr classq8 q score1 letterD> td classtd1> div> div>Alcohol/div> div classhelper> div classl_arrow>/div> div classdesc>Alcohol/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>1/div> /div> /td> /tr> tr> td classtable_result td1> div> div>Your score/div> /div> /td> td classtable_result result2> div> div>0/div> /div> /td> /tr> /table> div classv_arr1>img srcimg/varr.png altvarr/>/div> div classviev_results1>img srcimg/results.png altresults/>/div> div styleclear:both>/div> /div> div classtable4> div classt_title text_arial>HASBLED clinical risk estimation. Adapted from Pisters et al./div> table classt1 blue_table> tr> td classtable_title td1> div> div>HAS BLEDbr>SCORE/div> /div> /td> td classtable_title td2> div> div>NUMBER OFbr>PATIENTS/div> /div> /td> td classtable_title td3> div> div>NUMBER OFbr>BLEEDING/div> /div> /td> td classtable_title td4> div> div>BLEEDS PERbr>100 PATIENT YEARS/div> /div> /td> /tr> tr classq0 active risk_score1.13%> td classtd1> div> div>0/div> /div> /td> td classtd2> div> div>798/div> /div> /td> td classtd3> div> div>9/div> /div> /td> td classtd4> div> div>1.13/div> /div> /td> /tr> tr classq1 risk_score1.02%> td classtd1> div> div>1/div> /div> /td> td classtd2> div> div>1286/div> /div> /td> td classtd3> div> div>13/div> /div> /td> td classtd4> div> div>1.02/div> /div> /td> /tr> tr classq2 risk_score1.88%> td classtd1> div> div>2/div> /div> /td> td classtd2> div> div>744/div> /div> /td> td classtd3> div> div>14/div> /div> /td> td classtd4> div> div>1.88/div> /div> /td> /tr> tr classq3 risk_score3.74%> td classtd1> div> div>3/div> /div> /td> td classtd2> div> div>187/div> /div> /td> td classtd3> div> div>7/div> /div> /td> td classtd4> div> div>3.74/div> /div> /td> /tr> tr classq4 risk_score8.70%> td classtd1> div> div>4/div> /div> /td> td classtd2> div> div>46/div> /div> /td> td classtd3> div> div>4/div> /div> /td> td classtd4> div> div>8.70/div> /div> /td> /tr> tr classq5 risk_score12.50%> td classtd1> div> div>5/div> /div> /td> td classtd2> div> div>8/div> /div> /td> td classtd3> div> div>1/div> /div> /td> td classtd4> div> div>12.50/div> /div> /td> /tr> tr classq6 risk_score0%> td classtd1> div> div>6/div> /div> /td> td classtd2> div> div>2/div> /div> /td> td classtd3> div> div>0/div> /div> /td> td classtd4> div> div>0/div> /div> /td> /tr> tr classq7 risk_score0%> td classtd1> div> div>7/div> /div> /td> td classtd2> div> div>---/div> /div> /td> td classtd3> div> div>---/div> /div> /td> td classtd4> div> div>---/div> /div> /td> /tr> tr classq8 risk_score0%> td classtd1> div> div>8/div> /div> /td> td classtd2> div> div>---/div> /div> /td> td classtd3> div> div>---/div> /div> /td> td classtd4> div> div>---/div> /div> /td> /tr> tr classq9 risk_score0%> td classtd1> div> div>9/div> /div> /td> td classtd2> div> div>---/div> /div> /td> td classtd3> div> div>---/div> /div> /td> td classtd4> div> div>---/div> /div> /td> /tr> tr classq10 total> td classtd1> div> div>Total/div> /div> /td> td classtd2> div> div>798/div> /div> /td> td classtd3> div> div>9/div> /div> /td> td classtd4 idtotal_risk> div> div>1.13/div> /div> /td> /tr> /table> /div> div styleclear:both>/div> /div> div classthird_group> div classtable5> div classt_title text_arial>Classificaton of AF-related symptoms (EHRA score)/div> table classt1 pink_table> tr classq1 q scoreEHRAI> td classtd1> div> div>EHRA I/div> div classhelper> div classl_arrow>/div> div classdesc>/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>No symptoms/div> /div> /td> /tr> tr classq2 q scoreEHRAII> td classtd1> div> div>EHRA II/div> div classhelper> div classl_arrow>/div> div classdesc>Mild symptoms; normal daily activity not affected/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>Mild symptoms; normal daily activity not affected/div> /div> /td> /tr> tr classq3 q scoreEHRAIII> td classtd1> div> div>EHRA III/div> div classhelper> div classl_arrow>/div> div classdesc>Severe symptoms; normal daily activity affected/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>Severe symptoms; normal daily activity affected/div> /div> /td> /tr> tr classq4 q scoreEHRAIV> td classtd1> div> div>EHRA IV/div> div classhelper> div classl_arrow>/div> div classdesc>Disabling symptoms; normal daily activity discontinued/div> div classarrow>/div> /div> /div> /td> td classtd2> div> div>Disabling symptoms; normal daily activity discontinued/div> /div> /td> /tr> /table> /div> !--span classpatient_stent_btn>patient has a stent/span>--> div classv_arr2>img srcimg/varr2.png altvarr/>/div> /div> div classcopy-type> label>Select Clipboard text type : /label> div classtype1 type> div classtype1_value type_value idtype1_value>CHA2DS2-VAScspan classchadsvasc_result>not filled in/span>; HASBLEDspan classhasbled_result>not filled in/span>span classehra_result>/span> /div> div classcopy_paste_btm onclickcopy_to_clipboard(1); data-clipboard-target#type1_value> span classnotcopied notcopied1>copy to clipboard/span> span classcopied copied1>copied to clipboard/span> /div> div styleclear:both;>/div> /div> div classtype2 type> div classtype2_value type_value idtype2_value>span classcha2ds2_word>cha2ds2-vasc/span>span classchadsvasc_result>not filled in/span>; span classhasbled_word>hasbled/span>span classhasbled_result>not filled in/span>span classehra_result>/span>/div> div classcopy_paste_btm onclickcopy_to_clipboard(2); data-clipboard-target#type2_value> span classnotcopied notcopied2>copy to clipboard/span> span classcopied copied2>copied to clipboard/span> /div> div styleclear:both;>/div> /div> div classtype3 type> div classtype3_value type_value idtype3_value>span classcha2ds2_word>cha2ds2-vasc/span>span classchadsvasc_result>not filled in/span>span classrisk_score1>/span>; span classhasbled_word>hasbled/span>span classhasbled_result>not filled in/span>span classrisk_score2>/span>span classehra_result>/span>/div> div classcopy_paste_btm onclickcopy_to_clipboard(3); data-clipboard-target#type3_value> span classnotcopied notcopied3>copy to clipboard/span> span classcopied copied3>copied to clipboard/span> /div> div styleclear:both;>/div> /div> /div> div classfourth_group> div classbtn_block> div classbtn2> div classpopup_table> !--span classclose_btn>img srcimg/popup-closeButton.png />/span>--> div classnewtable> table classpatient_stent> tr classred_line> th>Haemorrhagic risk/th> th>Stroke risk/th> th>Clinical setting/th> th>Recommendations according to EHRA / ESC / EAPCI 2014 consensus document/th> /tr> tr classhasbled_s> td classhasbled_level2_class1>Low or moderatebr> (HAS-BLED 0-2)/td> td classhasbled_level1_class1>Moderatebr> (CHAsub>2/sub>DSsub>2/sub>-VASC 1 in males) /td> td classhasbled_level3_class1>Stable CAD/td> td> div> At least b>4 weeks/b> (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day /div> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) /div> div> b>Lifelong/b>: OAC /div> /td> /tr> tr classhasbled_s> td classhasbled_level2_class1>/td> td classhasbled_level1_class2>Highbr> (CHAsub>2/sub>DSsub>2/sub>-VASC ≥2)/td> td classhasbled_level3_class1>Stable CAD/td> td> div> At least b>4 weeks/b> (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day /div> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) /div> div> b>Lifelong/b>: OAC /div> /td> /tr> tr classhasbled_s> td classhasbled_level2_class1>/td> td classhasbled_level1_class1>Moderatebr> (CHAsub>2/sub>DSsub>2/sub>-VASC 1 in males) /td> td classhasbled_level3_class2>ACS/td> td> div> b>6 months/b>: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day /div> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) /div> div> b>Lifelong/b>: OAC /div> /td> /tr> tr classhasbled_s> td classtd-border hasbled_level2_class1>/td> td classtd-border hasbled_level1_class2>Highbr> (CHAsub>2/sub>DSsub>2/sub>-VASC ≥2)/td> td classtd-border hasbled_level3_class2>ACS/td> td classtd-border> div> b>6 months/b>: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day /div> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) /div> div> b>Lifelong/b>: OAC /div> /td> /tr> tr> td classhasbled_level2_class2>Highbr> (HAS-BLED ≥3)/td> td classhasbled_level1_class1>Moderatebr> (CHAsub>2/sub>DSsub>2/sub>-VASC 1 in males) /td> td classhasbled_level3_class1> Stable CAD/td> td> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day /div> div> b>Lifelong/b>: OAC /div> /td> /tr> tr> td classhasbled_level2_class2>/td> td classhasbled_level1_class2>Highbr> (CHAsub>2/sub>DSsub>2/sub>-VASC ≥2)/td> td classhasbled_level3_class1>Stable CAD/td> td> div> b>4 weeks/b>: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day /div> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) /div> div> b>Lifelong/b>: OAC /div> /td> /tr> tr> td classhasbled_level2_class2>/td> td classhasbled_level1_class1>Moderatebr> (CHAsub>2/sub>DSsub>2/sub>-VASC 1 in males) /td> td classhasbled_level3_class2>ACS/td> td> div> b>4 weeks/b>: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/daysup>d/sup> /div> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) /div> div> b>Lifelong/b>: OAC /div> /td> /tr> tr> td classhasbled_level2_class2>/td> td classhasbled_level1_class2>Highbr> (CHAsub>2/sub>DSsub>2/sub>-VASC ≥2)/td> td classhasbled_level3_class2>ACS/td> td> div> b>4 weeks/b>: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/daysup>d/sup> /div> div> b>Up to 12th month/b>: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) /div> div> b>Lifelong/b>: OAC /div> /td> /tr> /table> /div> /div> a href# classcopy_paste_btm btn_coronary_stent>Patient has a recent coronary stent/a> /div> div styleclear:both>/div> /div> /div> /div> /div> !--div classbg_popup>/div>--> div classdisclaim> Please be aware that the CHA2DS2Vasc risk score is only validated in non-valvular atrial fibrillation! For educational purposes only./br> By Jonas de Jong, MD, PhD, cardiologist. Suggestions for improvement are welcome at: a hrefmailto:dejong@stoneripple.com>dejong@stoneripple.com/a> .br>br> b>References:/b>/br> ul> li>a hrefhttp://journal.publications.chestnet.org/data/Journals/CHEST/20451/100134.pdf>Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user- friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; March 18 Epub ahead of print/a>/li> li>a hrefhttp://europace.oxfordjournals.org/content/12/10/1360.full.pdf>EHRA / EACT / ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010 Oct;12(10):1360-420. doi: 10.1093/europace/euq350./a>/li> li>a hrefhttp://stroke.ahajournals.org/content/41/12/2731.full.pdf>Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010 Dec;41(12):2731-8. doi: 10.1161/STROKEAHA.110.590257. Epub 2010 Oct 21./a>/li> li>a hrefhttp://journal.publications.chestnet.org/data/Journals/CHEST/22081/chest.09-1584.pdf>Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263–272/a>/li> li>a hrefhttp://eurheartj.oxfordjournals.org/content/early/2014/08/21/eurheartj.ehu298.full.pdf>Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014 Aug 25. pii: ehu298./a>/li> li>a hrefhttp://dx.doi.org/10.1016/j.jacc.2015.08.033>Van den Ham et al. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation. JACC. 2015./a>/li> /ul> /div> script typetext/javascript>jQuery(.copy-type #type-select).change(function(){jQuery(.copy-type).find(span).each(function(){jQuery(this).hide();})var clip_typejQuery(#type-select).val();jQuery(.copy-type #+clip_type).show();});/script>/body>/html>
Subdomains
Date
Domain
IP
www.chadsvasc.org
2014-07-17
104.28.23.73
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]